Ironwood Pharmaceuticals News

Ironwood Pharmaceuticals (NASDAQ:IRWD): Analysts Stay Bullish Despite Recent Stock Plunge

TipRanksMar 17 00:36

Ironwood Pharmaceuticals Analyst Ratings

BenzingaMar 2 01:59

Ironwood Pharmaceuticals: Strong Buy Rating on LINZESS Performance and Apraglutide Market Potential

TipRanksMar 1 04:16

Ironwood Pharmaceuticals Analyst Ratings

BenzingaFeb 16 23:56

Ironwood Pharmaceuticals Receives 'Buy' Rating From Analyst Amid Strong Performance and Promising Drug Pipeline

TipRanksFeb 16 03:06

Ironwood Pharmaceuticals Analyst Ratings

BenzingaJan 17 23:05

Wells Fargo Initiates Coverage On Ironwood Pharmaceuticals With Overweight Rating, Announces Price Target of $20

BenzingaDec 14, 2023 20:39

Ironwood Pharmaceuticals Analyst Ratings

BenzingaDec 14, 2023 20:34

Ironwood Pharmaceuticals' Apraglutide Shows Promising Results in STARS Nutrition and VectivBio Trials: An Emphasis on Jason Butler's Buy Rating

TipRanksOct 17, 2023 02:55

JMP Securities Initiates Coverage On Ironwood Pharmaceuticals With Market Outperform Rating, Announces Price Target of $22

BenzingaSep 28, 2023 17:55

Ironwood Pharmaceuticals Analyst Ratings

BenzingaSep 28, 2023 17:54

Piper Sandler Adjusts Price Target on Ironwood Pharmaceuticals to $19 From $16, Maintains Overweight Rating

MT NewswiresMay 23, 2023 21:17

Piper Sandler Maintains Overweight on Ironwood Pharmaceuticals, Raises Price Target to $19

BenzingaMay 23, 2023 21:03